^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tevimbra (tislelizumab-jsgr)

    i
    Other names: BGB-A317, BGB A317, VDT482, BGBA317, VDT 482, VDT-482
    Company:
    BeOne Medicines
    Drug class:
    PD1 inhibitor
    Related drugs:
    24h
    DTP-HER2: A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer (clinicaltrials.gov)
    P2, N=76, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Tevimbra (tislelizumab-jsgr) • Aidixi (disitamab vedotin) • Kolupin (tunlametinib)
    2d
    Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors (clinicaltrials.gov)
    P2, N=189, Completed, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2026 | Trial primary completion date: Jun 2026 --> Mar 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Herceptin (trastuzumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    2d
    Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma. (clinicaltrials.gov)
    P2, N=36, Completed, Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting --> Completed | Trial completion date: Dec 2025 --> Jul 2025
    Trial completion • Trial completion date
    |
    Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr)
    2d
    SOLTI-2101: Advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer (2023-508828-35-01)
    P2/3, N=316, Completed, Solti Group | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HER-2 negative + ER positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    Ibrance (palbociclib) • Tevimbra (tislelizumab-jsgr) • Kisqali (ribociclib)
    2d
    LBL-007-CN-004: A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors (clinicaltrials.gov)
    P1/2, N=98, Completed, Nanjing Leads Biolabs Co.,Ltd | Recruiting --> Completed | N=490 --> 98 | Trial completion date: Jul 2026 --> Jan 2026 | Trial primary completion date: May 2026 --> Jan 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • docetaxel • Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007)
    3d
    First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in adults with advanced or metastatic esophageal squamous cell carcinoma: a Japanese subgroup analysis of RATIONALE-306 with ≥ 3 years of follow-up. (PubMed, Esophagus)
    After 3 years, first-line tislelizumab plus chemotherapy demonstrated sustained efficacy and a tolerable safety profile in Japanese patients with unresectable locally advanced/metastatic ESCC, consistent with the global RATIONALE-306 population.
    Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • Tevimbra (tislelizumab-jsgr)
    3d
    Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases (clinicaltrials.gov)
    P2, N=50, Recruiting, Ruijin Hospital
    New P2 trial
    |
    Tyvyt (sintilimab) • Tevimbra (tislelizumab-jsgr) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    4d
    Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-line (clinicaltrials.gov)
    P2, N=80, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tyvyt (sintilimab) • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • Stivarga (regorafenib)
    4d
    Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC (clinicaltrials.gov)
    P1, N=288, Recruiting, Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • carboplatin • docetaxel • Tevimbra (tislelizumab-jsgr) • Ivesa (firmonertinib) • Yidafan (ivonescimab)
    4d
    A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, NYU Langone Health | Recruiting --> Active, not recruiting | Trial completion date: Jan 2026 --> Jul 2026
    Enrollment closed • Trial completion date
    |
    gemcitabine • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Ilaris (canakinumab)
    4d
    A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cance (clinicaltrials.gov)
    P3, N=562, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P3 trial
    |
    carboplatin • Tevimbra (tislelizumab-jsgr) • etoposide IV • izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1)
    7d
    IN10018 Combination Therapy in Previously-treated Solid Tumors (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, InxMed (Shanghai) Co., Ltd. | N=72 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • ifebemtinib (IN10018)